BioNTech SE (22UA.XETRA) stock: Winston Score, insiders and Congress trades

BioNTech is a German biotechnology company that develops medicines using a technology called mRNA, which teaches the body's cells to fight diseases. It became widely known for co-developing the COVID-19 vaccine with Pfizer, which was one of the first mRNA vaccines ever approved for widespread use. The company focuses on cancer treatments, infectious diseases, and other serious illnesses. BioNTech earns money mainly through product sales and royalties from its COVID-19 vaccine partnership with Pfizer, though vaccine revenues have dropped sharply since the pandemic peak. The company is headquartered in Mainz, Germany, and operates globally, with a strong cash reserve built during the pandemic that funds its ongoing research pipeline. Its biggest growth opportunity is its cancer immunotherapy pipeline, but the main risk is that it has not yet successfully commercialized a second major product, making it heavily dependent on a single revenue source.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-07.